Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

Recruiting in Palo Alto (17 mi)

Overseen bySami Noujaim, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: University of South Florida

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The goal of this pilot study is to explore the efficacy of chloroquine in terminating persistent AF and assess its potential role as a pharmacological cardioversion agent for the management of AF.

Research Team

Sami Noujaim, PhD

Principal Investigator

University of South Florida

Eligibility Criteria

Inclusion Criteria

Age 18 years and older

History of symptomatic persistent AF Persistent AF - defined as continuous AF that is sustained more than 7 days but less than 12 months. Episodes of AF of ≥ 48 hours duration in which a decision is made to terminate with electrical or pharmacological cardioversion prior to 7 days will also be classified as persistent AF

AF must be documented at least once either by ECG, event monitoring, loop recorder, telemetry, trans-telephonic monitoring, pacemaker or cardiac defibrillator readouts within 24 months prior to enrollment

See 2 more

Treatment Details

Interventions

Chloroquine Phosphate (Anti-malarial drug)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Chloroquine PhosphateExperimental Treatment1 Intervention

Chloroquine Phosphate will be provided at 500 mg dosage strength for oral administration. Patient will be instructed to take 2 tablets per day on the first two days and 1 tablet each day for the next 12 days for a total of 14 days treatment.